Physician profile
Amber Parker
NPI 1619573409
$444.19
in general payments reported to CMS, 2019-2025
16 companies · $48.25 in 2025
The $48.25 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $343 · 2023: $33.39 · 2024: $19.64 · 2025: $48.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $101.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $70.70 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.91 | 2021 | |
| Abbvie INC. | $45.94 | 2021 | |
| Boston Scientific Corporation | $38.68 | 2024-2025 | Varithena Administration Pack |
| Electromed, INC. | $30.80 | 2021 | |
| Emd Serono, INC. | $29.21 | 2025 | |
| Novo Nordisk INC | $29.02 | 2021 | |
| Lilly USA, LLC | $27.80 | 2021 | |
| Dexcom, INC. | $19.45 | 2023 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $16.94 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.35 | 2021 | |
| Genzyme Corporation | $14.53 | 2021 | |
| Neurocrine Biosciences, INC. | $14.36 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.94 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $13.03 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.